Peng Yan, Wang Helen H
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachussets, USA.
Diagn Cytopathol. 2006 Aug;34(8):585-8. doi: 10.1002/dc.20526.
HPV testing for high-risk types is the preferred method to triage women with atypical squamous cells (ASC) on ThinPrep Pap tests for management. The impact of this practice on the cytopathologists' interpretation is unknown. A significant percentage of providers at the Beth Israel Deaconess Medical Center (BIDMC) are not requesting reflex HPV testing. This offers a unique opportunity to examine its impact. Consecutive ThinPreps submitted to the cytology laboratory at the BIDMC for a 3-mo period were identified retrospectively. The ThinPreps were divided into those with a request for reflex HPV testing (reflex testing request group), those without such a request, and those with a request for HPV testing regardless of the diagnosis. Cytologic diagnoses, results of HPV testing and subsequent cervical biopsies within 6 mo after the ThinPrep were recorded and correlated in these cases. A total of 4,590 ThinPreps were processed during this period. 2,659 had a request for reflex HPV testing, 1,849 did not have such a request, and 82 had a request for HPV testing regardless of diagnosis. The numbers (%) of abnormal results in these three groups were 155 (5.8%), 141 (7.6%), and 22 (27%), respectively. The ASC:SIL ratios for these three groups were 1.2, 0.86, and 0.62, respectively. 38/71 (54%) women with ASC in the reflex testing request group were positive for high-risk HPV types. Of those with ASC in the reflex testing request and no request groups, 15/73 (21%) and 12/56 (21%) underwent biopsies with 2 (of 15) and 2 (of 12) showing HSIL on histology, respectively. Our study demonstrates that at our institution a request for reflex HPV testing did not significantly affect cytopathologists' interpretation of ThinPreps. Furthermore, HPV testing did not seem to have influenced the subsequent management of women with ASC diagnosis.
高危型人乳头瘤病毒(HPV)检测是对液基薄层制片巴氏试验中出现非典型鳞状细胞(ASC)的女性进行分流管理的首选方法。这种做法对细胞病理学家的诊断结果有何影响尚不清楚。贝斯以色列女执事医疗中心(BIDMC)有相当比例的医疗服务提供者并未要求进行HPV检测的后续检查。这为研究其影响提供了一个独特的机会。回顾性确定连续3个月提交至BIDMC细胞学实验室的液基薄层制片。这些液基薄层制片被分为要求进行HPV检测后续检查的(检测后续检查申请组)、未提出此类要求的以及无论诊断结果如何均要求进行HPV检测的。记录这些病例中液基薄层制片后6个月内的细胞学诊断、HPV检测结果及后续宫颈活检情况,并进行相关性分析。在此期间共处理了4590份液基薄层制片。2659份要求进行HPV检测后续检查,1849份未提出此类要求,82份无论诊断结果如何均要求进行HPV检测。这三组中的异常结果数量(百分比)分别为155例(5.8%)、141例(7.6%)和22例(27%)。这三组的ASC:SIL比值分别为1.2、0.86和0.62。检测后续检查申请组中71例ASC女性中有38例(54%)高危型HPV检测呈阳性。在检测后续检查申请组和未申请组中有ASC的女性中,分别有15/73(21%)和12/56(21%)接受了活检,其中15例中有2例、12例中有2例组织学检查显示为高级别鳞状上皮内病变(HSIL)。我们的研究表明,在我们机构,要求进行HPV检测后续检查对细胞病理学家对液基薄层制片的诊断结果没有显著影响。此外,HPV检测似乎并未影响ASC诊断女性的后续管理。